Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study

Peer Review reports

Original Submission
19 Jun 2019	Submitted	Original manuscript
6 Jul 2019	Author responded	Author comments - Tsunekazu Mizushima
Resubmission - Version 2
6 Jul 2019	Submitted	Manuscript version 2
29 Jul 2019	Reviewed	Reviewer Report - Soichiro Ishihara
4 Aug 2019	Reviewed	Reviewer Report - Takayuki Yoshino
12 Aug 2019	Author responded	Author comments - Tsunekazu Mizushima
Resubmission - Version 3
12 Aug 2019	Submitted	Manuscript version 3
26 Aug 2019	Author responded	Author comments - Tsunekazu Mizushima
Resubmission - Version 4
26 Aug 2019	Submitted	Manuscript version 4
29 Aug 2019	Author responded	Author comments - Tsunekazu Mizushima
Resubmission - Version 5
29 Aug 2019	Submitted	Manuscript version 5
Publishing
2 Sep 2019	Editorially accepted
18 Sep 2019	Article published	10.1186/s12885-019-6122-2

Back to article page